MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.bbmt.2018.10.015

Медицинская библиотека · Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018

Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal.

Li Ang, Wu Qian, Davis Chris, Kirtane Kedar S, Pham Phuqui D, Sorror Mohamed L, Lee Stephanie J, Gopal Ajay K, Dong Jing-Fei, Garcia David A, Weiss Noel S, R Hingorani Sangeeta

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Transplant-associated thrombotic microangiopathy (TA-TMA) after allogeneic hematopoietic cell transplantation (HCT) has not been well characterized in large population studies with clinically adjudicated cases. We performed a retrospective cohort study of adults who underwent allogeneic HCT between 2006 and 2015 to determine the incidence of and risk factors for TA-TMA and to describe its natural history and response to immunosuppressant withdrawal management. Among 2145 patients in this study, 192 developed TA-TMA with a cumulative incidence of 7.6% by 100days post-transplant. Independent pretransplant risk factors included the receipt of a second (or third) allogeneic HCT, HLA-mismatched donor, and myeloablative conditioning with or without total body irradiation; post-transplant risk factors included the antecedent development of acute graft-versus-host disease, diffuse alveolar hemorrhage, bacteremia, invasive aspergillosis, BK viremia, and higher sirolimus trough level. Among TA-TMA patients 27% achieved hematologic resolution and 57% remained alive as of 90days after diagnosis. Antecedent risk factors stratified patients into different survival groups, and immunosuppressant withdrawal alone did not improve patient outcomes. In conclusion, TA-TMA is a heterogenous disease that occurs after allogeneic transplantation. Management with immunosuppressant withdrawal does not impact patient outcomes. Until further evidence becomes available, the management of TA-TMA should focus on the treatment of underlying diseases.

Для цитирования: Li Ang, Wu Qian, Davis Chris, Kirtane Kedar S, Pham Phuqui D, Sorror Mohamed L, Lee Stephanie J, Gopal Ajay K, Dong Jing-Fei, Garcia David A, Weiss Noel S, R Hingorani Sangeeta. Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018. DOI: 10.1016/j.bbmt.2018.10.015.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.